Clinical Trial Update: Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates the combination of VB10.16 (Nykode) and atezolizumab in HPV-16 positive cervical cancer; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• VB10.16

Snippet

Sponsor: Nykode Therapeutics ASA | Conditions: Cervical Cancer, Cervix Cancer | Phase 2 | Status: COMPLETED